Sameer Desai joined Ropes & Gray's corporate department in 2021, and has represented a broad range of private equity and strategic clients in a variety of transactions including complex licenses and collaborations, royalty monetizations, mergers and acquisitions, and commercial agreements.

During law school, Sameer served as an editorial board member of the Boston College Law Review and as a treasurer of the Environmental Law Society. Sameer also worked in the Boston College Civil Litigation Law Clinic working with indigent clients in securing housing. Prior to law school, Sameer worked at a global pharmaceutical company providing compliance and data security services.


  • Advised Accutar Biotechnology in a strategic partnership with Evommune focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.
  • Represented Blackstone Life Sciences in the purchase of Sutro Biopharma’s royalty interests in Vaxcyte’s products, including VAX-24, for up to $390 million.
  • Advised ImmunoGen, a leader in the field of antibody-drug conjugates (ADC) for the treatment of cancer, in a term loan financing for up to $175 million with entities managed by Pharmakon Advisors.
  • Represented uniQure N.V. in agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX, the first gene therapy approved for adults with hemophilia B, to HealthCare Royalty and Sagard Healthcare for up to $400 million.
  • Represented CANbridge Pharmaceuticals, a China-based biopharmaceutical company, in connection with its exclusive license agreement with UMass Medical School relating to the development and commercialization of a novel second-generation gene therapy for treatment of spinal muscular atrophy (SMA).

Areas of Practice